ADVERSE-EFFECTS OF MONOBACTAMS AND CARBAPENEMS

被引:29
作者
ALVAN, G [1 ]
NORD, CE [1 ]
机构
[1] HUDDINGE UNIV HOSP,KAROLINSKA INST,DEPT CLIN PHARMACOL,STOCKHOLM,SWEDEN
关键词
D O I
10.2165/00002018-199512050-00003
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Monobactams and carbapenems are 2 classes of beta-lactam antibiotics that were introduced in the 1980s. This review considers the monobactam aztreonam and the carbapenems imipenem and meropenem, Imipenem is administered together with cilastatin, which inhibits the enzymatic breakdown of imipenem in the kidney, The antibacterial activities of these drugs are-quite different from older beta-lactams. Aztreonam is directed towards aerobic Gram-negative bacteria, especially Pseudomonas aeruginosa, while imipenem and meropenem are active against both aerobic and anaerobic Gram-positive and Gram-negative bacteria. Thus, these drugs should be reserved for patients who have a special need for them. They are also structurally different from older beta-lactams-and possess different adverse drug reaction profiles. It was initially suggested that aztreonam would be less immunogenic than previous beta-lactams because reactive breakdown products acting as haptens are less likely to be formed. Clinical reports now support this assumption, and, in particular, cross hypersensitivity between aztreonam and other beta-lactams seems to be rare which makes the drug a useful therapeutic alternative. However, hypersensitivity to aztreonam does occur. The predominant concern in terms of adverse reactions to imipenem/cilastatin is the increased tendency to cause seizures compared with other beta-lactams. The risk of producing a seizure is highly associated with inadequate dose adjustment in relation to kidney function. If appropriate care is taken, seizures occur in less than 1% of patients treated. However, it is possible that concomitant administration of other drugs with neurotoxic profiles (e.g. theophylline and cyclosporin) given in overdose, may increase the risk of seizures. Meropenem has a similar adverse effect profile to imipenem/cilastatin; more clinical experience is required to assess its relative tolerability.
引用
收藏
页码:305 / 313
页数:9
相关论文
共 34 条
[11]  
Hegelmaier C., Hutig H.B., Kalbheim H.J., Antibiotikaassoziierte pseudomenbranöse Kolitis — eine literaturgestützte Fallanalyse, Klin Wochenschr, 69, 26, pp. 57-60, (1991)
[12]  
Moore R.D., Lerner S.A., Levine D.P., Nephrotoxicity and ototoxicity of aztreonam versus aminoglycoside therapy in seriously ill nonneutropenic patients, J Infect Dis, 165, (1992)
[13]  
Rietbroek R.C., Hoitsma A.J., Koene R.A.P., Aztreonam can safely be used in combination with cyclosporin without aggravating nephrotoxicity, Transplant Int, 2, (1989)
[14]  
Buckley M.M., Brogden R.N., Barradell R.B., Et al., Imipenem/cilastatin: a reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy, Drugs, 44, (1992)
[15]  
Snavely S.R., Hodges G.R., The neurotoxicity of antibacterial agents, Ann Intern Med, 101, pp. 92-104, (1984)
[16]  
Eng R.H.K., Munsif A.N., Yangco B.G., Et al., Seizure propensity with imipenem, Arch Intern Med, 149, (1989)
[17]  
Brown R.B., Sands M., Morris A.B., Seizure propensity with imipenem [letter], Arch Intern Med, 150, (1990)
[18]  
Choucino C., Chopra A., Khardori N., Incidence of seizures in patients treated with imipenem/cilastatin in a teaching hospital [abstract], Clin Res, 40, (1992)
[19]  
Pestotnik S.L., Classen D.C., Evans R.S., Et al., Prospective surveillance of imipenem/cilastatin use and associated seizures using a hospital information system, Ann Pharmacother, 27, pp. 497-501, (1993)
[20]  
Semel J.D., Allen N., Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole, South Med J, 84, (1991)